These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 21143001)

  • 21. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Twenty-five years of HIV/AIDS.
    Fauci AS
    Science; 2006 Jul; 313(5786):409. PubMed ID: 16873613
    [No Abstract]   [Full Text] [Related]  

  • 23. The obstetric face and challenge of HIV/AIDS.
    Guidozzi F; Black V
    Clin Obstet Gynecol; 2009 Jun; 52(2):270-84. PubMed ID: 19407534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peering into the future: searching for answers to old and new questions about HIV/AIDS.
    Henry WK; Alozie OK; Bonham S
    Minn Med; 2009 Oct; 92(10):50-4. PubMed ID: 19916275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV/AIDS: Latin America & Caribbean. Brazil: ten years after.
    Cohen J
    Science; 2006 Jul; 313(5786):484-7. PubMed ID: 16873654
    [No Abstract]   [Full Text] [Related]  

  • 26. [AIDS--the forgotten pandemic?].
    Bartens W
    Dtsch Med Wochenschr; 1999 Aug; 124(33):A7-8. PubMed ID: 10481753
    [No Abstract]   [Full Text] [Related]  

  • 27. [To finish theoretically with AIDS].
    Nau JY
    Rev Med Suisse; 2008 Dec; 4(183):2705. PubMed ID: 19157288
    [No Abstract]   [Full Text] [Related]  

  • 28. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs.
    Sharma P; Garg S
    Adv Drug Deliv Rev; 2010 Mar; 62(4-5):491-502. PubMed ID: 19931328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV/AIDS: Latin America & Caribbean. Overview: the overlooked epidemic.
    Cohen J
    Science; 2006 Jul; 313(5786):468-9. PubMed ID: 16873639
    [No Abstract]   [Full Text] [Related]  

  • 30. HIV/AIDS. Malawi: a suitable case for treatment.
    Cohen J
    Science; 2002 Aug; 297(5583):927-9. PubMed ID: 12169711
    [No Abstract]   [Full Text] [Related]  

  • 31. Exploring the use of novel drug delivery systems for antiretroviral drugs.
    Ojewole E; Mackraj I; Naidoo P; Govender T
    Eur J Pharm Biopharm; 2008 Nov; 70(3):697-710. PubMed ID: 18655830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanoparticle-based vaginal drug delivery systems for HIV prevention.
    Mallipeddi R; Rohan LC
    Expert Opin Drug Deliv; 2010 Jan; 7(1):37-48. PubMed ID: 20017659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prevention of wasting and opportunistic infections in HIV-infected patients in West Africa: a realistic and necessary strategy before antiretroviral treatment].
    Ledru é ; Sanou PT; Dembele M; Dahourou H; Zoubga A; Durand G
    Sante; 1999; 9(5):293-300. PubMed ID: 10657773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [AIDS situation in Spain: the present and future prospects].
    Parras Vázquez F
    Rev Esp Salud Publica; 1997; 71(6):511-4. PubMed ID: 9477706
    [No Abstract]   [Full Text] [Related]  

  • 35. Nanotechnology and HIV: potential applications for treatment and prevention.
    Kim PS; Read SW
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(6):693-702. PubMed ID: 20860050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-retrovirals for treatment and prevention--time for new paradigms in our response to the HIV/AIDS epidemic?
    Abdool Karim Q; Bayer R
    Dev World Bioeth; 2013 Aug; 13(2):ii-iii. PubMed ID: 23865982
    [No Abstract]   [Full Text] [Related]  

  • 37. UK Guideline for the use of post-exposure prophylaxis for HIV following sexual exposure.
    Fisher M; Benn P; Evans B; Pozniak A; Jones M; Maclean S; Davidson O; Summerside J; Hawkins D;
    Int J STD AIDS; 2006 Feb; 17(2):81-92. PubMed ID: 16464267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nano-microbicides: challenges in drug delivery, patient ethics and intellectual property in the war against HIV/AIDS.
    du Toit LC; Pillay V; Choonara YE
    Adv Drug Deliv Rev; 2010 Mar; 62(4-5):532-46. PubMed ID: 19922751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Surfactants as agents for the individual prevention of HIV/AIDS].
    Krivorutchenko IuL
    Mikrobiol Z; 1999; 61(1):95-103. PubMed ID: 10330875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.